GLP1R and type 2 diabetes mellitus: Moreover, our study also supplemented the previous cost-effectiveness analyses of once-weekly semaglutide versus other GLP-1 RAs in China, which reported that once-weekly semaglutide was dominant versus polyethylene glycol loxenatide, and was cost-effective or even dominant versus dulaglutide for type 2 diabetes patients uncontrolled on metformin after semaglutide was included in the national reimbursement drug list through price negotiation [43–45].